GlassScriptPhysician profile
Robert P Guilbault
NPI 1275581092
$17,386.07
in general payments reported to CMS, 2019-2025
56 companies · $2,593 in 2025
The $2,593 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,010 · 2020: $2,177 · 2021: $2,739 · 2022: $2,888 · 2023: $2,840 · 2024: $2,138 · 2025: $2,593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,571.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,545.76 | 2019-2025 | |
| Amgen INC. | $2,034.06 | 2019-2025 | Evenity, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,699.19 | 2019-2025 | Breztri, Farxiga, Bevespi Aerosphere |
| Lilly USA, LLC | $1,469.33 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $1,139.58 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $987.58 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $926.29 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Astellas Pharma US INC | $693.70 | 2019-2023 | Myrbetriq |
| Novo Nordisk INC | $676.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $486.60 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $373.65 | 2019-2025 | Trintellix |
| Glaxosmithkline, LLC. | $353.24 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Allergan, INC. | $323.40 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $320.48 | 2019-2023 | Austedo Xr |
| Sanofi-Aventis U.S. LLC | $298.10 | 2019-2024 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Guilbault listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.